Navidea Biopharmaceuticals Cost of Revenue | NAVB

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.

What is included in the cost of revenue

Cost Category	Examples
Production Costs	Materials, wages of production staff, depreciation of equipment
Service and Support	Customer service, user support, technical assistance
Delivery and Logistics	Packaging, delivery of goods to customers
Hosting and Infrastructure	Servers, cloud platforms (especially for IT and SaaS companies)
Content and Licenses	License purchases, production royalties (e.g., in streaming services)

Importance of the Metric

Helps to understand how costly the revenue-generating process is.
A high cost of revenue may indicate:
Poor cost control
Low operational efficiency
A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue Navidea Biopharmaceuticals

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
1.94 K	-	1.05 K	6.67 K	96.6 K	3.65 K	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
96.6 K	1.05 K	22 K

Quarterly Cost of Revenue Navidea Biopharmaceuticals

2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
1.43 K	473	-	-	1.43 K	473	-	-	-	-	609	-	82	357	609	-	195	238	6.13 K	-	38.1 K	35.4 K	318	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
38.1 K	82	6.13 K

Cost of Revenue of other stocks in the Biotechnology industry

Issuer	Cost of Revenue	Price	% 24h	Market Cap	Country
BioLineRx Ltd. BLRX	230 K	$ 2.52	1.17 %	$ 6.21 B	Israel
BioMarin Pharmaceutical BMRN	717 M	$ 61.35	0.06 %	$ 11.8 B	USA
BioNTech SE BNTX	642 M	$ 99.26	0.81 %	$ 24 B	Germany
Burford Capital Limited BUR	43.6 M	$ 3.63	3.93 %	$ 795 M	Britain
Amryt Pharma plc AMYT	106 M	-	-	$ 621 M	Britain
Catalyst Biosciences CBIO	5.42 M	$ 14.24	0.35 %	$ 1.27 B	USA
Codexis CDXS	9.34 M	$ 1.37	1.45 %	$ 119 M	USA
Cerus Corporation CERS	33.4 M	$ 2.61	0.38 %	$ 497 M	USA
AbbVie ABBV	18.2 B	$ 265.12	0.09 %	$ 469 B	USA
Coherus BioSciences CHRS	13.8 M	$ 1.17	1.48 %	$ 137 M	USA
Abeona Therapeutics ABEO	1.53 M	$ 5.43	2.65 %	$ 288 M	USA
Celldex Therapeutics CLDX	200 K	$ 31.48	1.16 %	$ 2.09 B	USA
CollPlant Biotechnologies Ltd. CLGN	835 K	$ 4.12	1.98 %	$ 50.3 M	Israel
Cocrystal Pharma COCP	406 K	$ 1.15	1.67 %	$ 13 M	USA
Crinetics Pharmaceuticals CRNX	1.08 M	$ 84.95	0.13 %	$ 7.99 B	USA
Collegium Pharmaceutical COLL	77.1 M	$ 22.64	0.85 %	$ 717 M	USA
Corcept Therapeutics Incorporated CORT	13 M	$ 118.51	4.93 %	$ 12.3 B	USA
Chimerix CMRX	447 K	-	-	$ 756 M	USA
CorMedix CRMD	22.1 M	$ 7.77	1.04 %	$ 560 K	USA
Champions Oncology CSBR	30.9 M	$ 4.95	0.38 %	$ 68.5 M	USA